PAK1 and neurodegenerative disease: PAK1 also regulates the expression of Ataxin-1 that is involved in spinocerebellar ataxia type I, suggesting that PAK1 inhibition may be a therapeutic approach in this orphan neurodegenerative disease (Bondar et al., 2018).